Display options
Cite
Jia J, Chang GL, Qin S, et al. Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial. Exp Ther Med. 2017;13(4):1554-1560doi: 10.3892/etm.2017.4111.
Jia, J., Chang, G. L., Qin, S., Chen, J., He, W. Y., Lu, K., Li, Y., & Zhang, D. Y. (2017). Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial. Experimental and therapeutic medicine, 13(4), 1554-1560. https://doi.org/10.3892/etm.2017.4111
Jia, Jun, et al. "Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial." Experimental and therapeutic medicine vol. 13,4 (2017): 1554-1560. doi: https://doi.org/10.3892/etm.2017.4111
Jia J, Chang GL, Qin S, Chen J, He WY, Lu K, Li Y, Zhang DY. Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial. Exp Ther Med. 2017 Apr;13(4):1554-1560. doi: 10.3892/etm.2017.4111. Epub 2017 Feb 08. PMID: 28413508; PMCID: PMC5377512.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2017 Apr;13(4):1554-1560. doi: 10.3892/etm.2017.4111. Epub 2017 Feb 08.

Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial.

Experimental and therapeutic medicine

Jun Jia, Guang-Lei Chang, Shu Qin, Jia Chen, Wen-Yan He, Kai Lu, Yong Li, Dong-Ying Zhang

Affiliations

  1. Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Yuanjiagang, Yuzhong, Chongqing 400016, P.R. China.
  2. Department of Basic Sciences, Center for Perinatal Biology, Division of Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.

PMID: 28413508 PMCID: PMC5377512 DOI: 10.3892/etm.2017.4111

Abstract

The present study compared the prognostic value of a marker, the C-terminal section of the arginine vasopressin prohormone (copeptin), with N-terminal B-type natriuretic peptide (NT-proBNP) in patients with severe acute decompensated heart failure. A prospective, observational cohort study was conducted in a tertiary care hospital and enrolled 129 patients with severe acute decompensated heart failure. Clinicians were blinded to investigational markers except NT-proBNP, and the study participants were followed up for 90 days. The end-point was a composite of cardiovascular death or re-hospitalization due to decompensated heart failure. Of the 129 patients enrolled, 47 reached the end-point and 82 were in a stable condition during follow-up. Receiver operating characteristic curve analysis revealed that the areas under curve for the prediction of adverse events within 90 days were similar for copeptin [0.602±0.052; 95% confidence interval (CI), 0.499-0.705], NT-proBNP (0.659±0.048; 95% CI, 0.565-0.753) and their combination (0.670±0.050; 95% CI, 0.573-0.767). Kaplan-Meier survival analysis showed that the predictive value of NT-proBNP regarding the probability of survival was superior compared with that of copeptin (log-rank test for trend, P=0.001 vs. 0.040). Furthermore, multivariate Cox proportional-hazards regression analysis revealed that increased NT-proBNP and copeptin plasma concentrations were significant independent predictors of adverse events. The present study provided evidence that copeptin has similar predictive properties compared with NT-proBNP regarding adverse events within 90-days in patients with severe acute decompensated heart failure, but that copeptin may not provide superior 90-day prediction compared to NT-proBNP.

Keywords: N-terminal B-type natriuretic peptide; adverse events; copeptin; heart failure; mortality

References

  1. Shock. 2007 Aug;28(2):219-26 - PubMed
  2. Circ Heart Fail. 2011 Sep;4(5):613-20 - PubMed
  3. Radiology. 1983 Sep;148(3):839-43 - PubMed
  4. Eur Heart J. 2008 Oct;29(19):2388-442 - PubMed
  5. Eur J Heart Fail. 2008 Sep;10(9):824-39 - PubMed
  6. Endocr Metab Immune Disord Drug Targets. 2013 Mar;13(1):68-75 - PubMed
  7. JAMA. 2005 Feb 2;293(5):572-80 - PubMed
  8. Nature. 1982 Jan 28;295(5847):299-303 - PubMed
  9. Neurology. 2011 Feb 8;76(6):563-6 - PubMed
  10. Neuro Endocrinol Lett. 2008 Jun;29(3):341-6 - PubMed
  11. Circulation. 2007 Jun 19;115(24):3103-10 - PubMed
  12. Clin Chem. 2006 Jan;52(1):112-9 - PubMed
  13. Eur Heart J. 1997 Feb;18(2):208-25 - PubMed
  14. BMC Med. 2012 Jan 20;10:7 - PubMed
  15. J Card Fail. 2007 Feb;13(1):42-9 - PubMed
  16. Stroke. 2010 Jul;41(7):1564-7 - PubMed
  17. Acad Emerg Med. 2011 Sep;18(9):947-58 - PubMed
  18. J Trauma. 2011 Nov;71(5):1194-8 - PubMed
  19. Eur J Clin Invest. 2006 Nov;36(11):771-8 - PubMed
  20. Crit Care. 2011;15(1):R1 - PubMed
  21. Eur Heart J. 2006 Feb;27(3):330-7 - PubMed
  22. Eur J Heart Fail. 2007 Aug;9(8):776-86 - PubMed
  23. Eur J Clin Invest. 2007 Feb;37(2):145-52 - PubMed
  24. Circulation. 1997 Jul 15;96(2):509-16 - PubMed
  25. Br J Cancer. 1994 Feb;69(2):260-3 - PubMed
  26. N Engl J Med. 2008 May 15;358(20):2148-59 - PubMed

Publication Types